2型糖尿病の疫学的予測

◆英語タイトル:EpiCast Report: Type 2 Diabetes - Epidemiology Forecast to 2025
◆商品コード:GDHCER120-16
◆発行会社(調査会社):GlobalData
◆発行日:2016年6月6日
◆ページ数:69
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥443,445見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥886,890見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD11,985 ⇒換算¥1,330,335見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、2型糖尿病の疫学的市場予測について調査・分析し、以下の構成でお届けいたします。
・イントロダクション
・2型糖尿病の概要
・リスク要因及び併存症
・主要地域の動向
・疫学的予測方法
・2型糖尿病の疫学的予測結果(有病率など)
・考察(結論、分析の限界・強み)
【レポートの概要】

EpiCast Report: Type 2 Diabetes – Epidemiology Forecast to 2025

Summary

Type 2 diabetes (T2D), formerly known as non-insulin dependent diabetes mellitus or adult-onset diabetes mellitus, is a chronic disorder of glucose equilibrium that results from the body’s inability to make use of available insulin along with relative insulin deficiency. T2D constitutes approximately 90% of all diabetes cases around the world; type 1 diabetes (T1D) and gestational diabetes make up the remaining 10% of the cases. Risk factors for T2D are broadly categorized as either modifiable or non-modifiable risk factors. Lifestyle factors such as obesity, physical inactivity, and dietary habits are modifiable risk factors, whereas family history and advancing age are non-modifiable risk factors. T2D is also associated with several comorbidities, such as CKD, CVD, hypertension, and dyslipidemia, which can worsen the quality of life of the patient, and can lead to poor therapeutic outcomes. Diabetes is one of the most common non-communicable diseases worldwide and is an escalating public health problem globally.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of T2D in the 9MM, from 116,871,808 diagnosed prevalent cases in 2015 to 151,907,657 diagnosed prevalent cases in 2025, with an Annual Growth Rate (AGR) of 3.00%. The projected increase in the diagnosed prevalent cases of T2D across all the markets covered in this analysis is attributed to the actual increase in the incidence of T2D along with the change in population demographics in the respective markets.

GlobalData epidemiologists utilized country-specific diagnosed prevalence data for T2D across the 9MM. Additionally, the epidemiological forecast for the diagnosed prevalent cases of T2D in the 9MM is supported by nationally representative longitudinal historical data obtained from studies in respective countries published in peer-reviewed journals or national healthcare databases, which provide a detailed insight into the epidemiology of the disease in these markets.

Scope

- The Type 2 Diabetes (T2D) EpiCast Report provides an overview of the risk factors and global trends of T2D in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, China, and India). It includes a 10-year epidemiology forecast of T2D diagnosed prevalent cases segmented by age (in ten-year increments beginning at ages 20-30 years and ending at age 80 years and older), sex, and comorbidities including chronic kidney disease (CKD), cardiovascular disease (CVD), overweight/obesity, hypertension, and dyslipidemia in these nine markets.
- The T2D epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy

The T2D EpiCast report will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global T2D market.
- Quantify patient populations in the global T2D market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for T2D therapeutics in each of the markets covered.
- Identify the percentage of T2D diagnosed prevalent cases by age, sex, and comorbidities.

【レポートの目次】

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.3 Global Trends 12
3.3.1 US 12
3.3.2 5EU 13
3.3.3 Japan 13
3.3.4 China and India 14
3.4 Forecast Methodology 14
3.4.1 Sources Used for Diagnosed Prevalence of T2D 19
3.4.2 Sources Not Used 30
3.4.3 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of T2D 31
3.5 Epidemiological Forecast for T2D (2015-2025) 42
3.5.1 Diagnosed Prevalent Cases of T2D 42
3.5.2 Age-Specific Diagnosed Prevalent Cases of T2D 44
3.5.3 Sex-Specific Diagnosed Prevalent Cases of T2D 46
3.5.4 Age-Standardized Diagnosed Prevalence of T2D 48
3.5.5 Prevalent Cases of Chronic Kidney Disease Among Diagnosed T2D Cases 49
3.5.6 Prevalent Cases of Cardiovascular Disease Among Diagnosed T2D Cases 50
3.5.7 Prevalent Cases of Overweight/Obesity Among Diagnosed T2D Cases 51
3.5.8 Prevalent Cases of Hypertension Among Diagnosed T2D Cases 52
3.5.9 Prevalent Cases of Dyslipidemia Among Diagnosed T2D Cases 53
3.6 Discussion 54
3.6.1 Epidemiological Forecast Insight 54
3.6.2 Limitations of the Analysis 55
3.6.3 Strengths of the Analysis 55
4 Appendix 57
4.1 Bibliography 57
4.2 About the Authors 64
4.2.1 Epidemiologists 64
4.2.2 Reviewers 65
4.2.3 Global Director of Therapy Analysis and Epidemiology 66
4.2.4 Global Head of Healthcare 66
4.3 About GlobalData 67
4.4 About EpiCast 67
4.5 Disclaimer 68

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for T2D 11
Table 2: 9MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of T2D 15
Table 3: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of CKD Among Diagnosed Prevalent Cases of T2D 16
Table 4: 8MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of CVD Among Diagnosed Prevalent Cases of T2D 16
Table 5: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Overweight and Obesity Among Diagnosed Prevalent Cases of T2D 17
Table 6: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Hypertension Among Diagnosed Prevalent Cases of T2D 18
Table 7: 8MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Dyslipidemia Among Diagnosed Prevalent Cases of T2D 18
Table 8: 9MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages ≥20 Years, N, 2015-2025 43
Table 9: 9MM, Age-Specific Diagnosed Prevalent Cases of T2D, Both Sexes, N (Row %), 2015 45
Table 10: 9MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, N (Row %), 2015 47

1.2 List of Figures
Figure 1: 9MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages ≥20 Years, N, 2015-2025 43
Figure 2: 9MM, Age-Specific Diagnosed Prevalent Cases of T2D, Both Sexes, N, 2015 46
Figure 3: 9MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, N, 2015 48
Figure 4: 9MM, Age-Standardized Diagnosed Prevalence of T2D (%), Ages ≥20 Years, by Sex, 2015 49
Figure 5: 9MM, Prevalent Cases of CKD Among Diagnosed T2D Cases, Both Sexes, Ages ≥20 Years, N, 2015 50
Figure 6: 8MM, Prevalent Cases of CVD Among Diagnosed T2D Cases, Both Sexes, Ages ≥20 Years, N, 2015 51
Figure 7: 9MM, Prevalent Cases of Overweight/Obesity Among Diagnosed T2D, Both Sexes, Ages ≥20 Years, N, 2015 52
Figure 8: 9MM, Prevalent Cases of Hypertension Among Diagnosed T2D, Both Sexes, Ages ≥20Years, N, 2015 53
Figure 9: 8MM, Prevalent Cases of Dyslipidemia Among Diagnosed T2D, Both Sexes, Ages ≥20 Years, N, 2015 54

★調査レポート[2型糖尿病の疫学的予測]販売に関する免責事項
★調査レポート[2型糖尿病の疫学的予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆